Next 10 |
First of Multiple Planned Global Submissions for Lifileucel in 2024 and 2025 Key Step in Global Expansion to Address >20,000 Patients Annually with Previously Treated Advanced Melanoma SAN CARLOS, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, In...
2024-06-28 04:05:00 ET Earlier this year, share prices of Iovance Biotherapeutics (NASDAQ: IOVA) were soaring after one of its therapies obtained approval from regulators. Iovance stock would go on to reach share price highs of more than $18. Today, however, the stock trades at less...
2024-06-26 16:55:19 ET Summary The Amtagvi launch has seen over 100 patients enrolled for therapy since approval, with potential for Q2'24 earnings to reflect some initial sales. IOVA's enrollment of the TILVANCE-301 continues, with updates on enrollment serving as a potential cat...
2024-06-20 07:00:08 ET Reni Benjamin from JMP Securities issued a price target of $23.00 for IOVA on 2024-06-20 06:20:00. The adjusted price target was set to $23.00. At the time of the announcement, IOVA was trading at $8. The overall price target consensus is at $23.83...
2024-06-16 16:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-10 10:15:00 ET It's always a nice surprise to see that a company you're invested in is making good on its opportunities and planning to grow on your behalf. In that vein, at the 2024 meeting of the American Society of Clinical Oncology (ASCO) on May 31, Iovance Biotherapeutics ...
2024-06-06 18:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-03 01:00:05 ET Benjamin Burnett from Stifel Nicolaus issued a price target of $28.00 for IOVA on 2024-05-31 15:08:00. The adjusted price target was set to $28.00. At the time of the announcement, IOVA was trading at $8.88. The overall price target consensus is at...
2024-05-30 09:14:24 ET Summary Data update from phase 1 BALLI-01 study, using UCART22 for the treatment of B-cell acute lymphoblastic leukemia, expected by the end of 2024. The global acute lymphoblastic leukemia therapeutics market is expected to increase to $8.29 billion by 2032...
2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...
News, Short Squeeze, Breakout and More Instantly...
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
First of Multiple Planned Global Submissions for Lifileucel in 2024 and 2025 Key Step in Global Expansion to Address >20,000 Patients Annually with Previously Treated Advanced Melanoma SAN CARLOS, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, In...
2024-06-28 04:05:00 ET Earlier this year, share prices of Iovance Biotherapeutics (NASDAQ: IOVA) were soaring after one of its therapies obtained approval from regulators. Iovance stock would go on to reach share price highs of more than $18. Today, however, the stock trades at less...
2024-06-20 07:00:08 ET Reni Benjamin from JMP Securities issued a price target of $23.00 for IOVA on 2024-06-20 06:20:00. The adjusted price target was set to $23.00. At the time of the announcement, IOVA was trading at $8. The overall price target consensus is at $23.83...